Tempus AI Costs, Outlook Send Stock Sharply Lower | Global News Avenue

tempus ai shares (tem) On the second day of the provider, 17% sunk on Tuesday AI The results and guidance of medical technology reports are poor, and as the company expands, costs rise.

Tempus released a fourth-quarter adjusted net loss of $0.18 per share, $0.02 higher than analysts surveyed by the Visible Alpha. Revenue rose 36% year-on-year to $200 million, but that was also lower than expected.

Sales in the genomics division grew by more than 30% to $120.4 million, and in the data and services business, they grew by nearly 45% to $80.2 million.

Company’s Non-GAAP Operating expenses rose 6.5% to $142.5 million. In a letter to shareholders, founder and CEO Erik Lefkofsky and CFO Jim Rogers explained that while tempus decreased during 2024 The hiring upgrades, but “a portion of non-GAAP operating expenses is part of the increase in non-GAAP operating expenses. The sales links associated with the expansion of territory to explain the overall test volume growth and the launch of our MRD analysis, as well as the Moderate growth and R&D personnel.”

Tempus sees adjustments throughout the year EBITDA $5 million, while the visible Alpha Outlook costs nearly $6 million. Its revenue was $1.24 billion, slightly higher than forecast.

Tempus AI stocks only started trading publicly last June, and despite the decline today, their initial price is still about 45% higher than their initial price.